secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001193125-25-286961
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes
--------------------------------------------------------------------------------

- DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.
- All patients reached Week 8; ~25% received second planned DURAVYU dose at Week 32.
- Masked safety data shows no safety signals, consistent with prior DURAVYU trials.
- Topline 56-week data for LUGANO on track for mid-2026; LUCIA data to follow closely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/0001193125-25-286961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-286961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer